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Rab5A generally accepted view considers phosphatidylinositol 3-monophosphate (PtdIns3P) as a lipid conﬁned to
the endosomal compartment where it regulates trafﬁcking pathways and is produced constitutively and
exclusively by class III phosphoinositide 3-kinase (PI3K). Recent evidence suggests that this phosphoinosi-
tide has a more complex role as a second messenger involved in different physiological and pathological
events and that speciﬁc intracellular localization of kinases and/or phosphatases is critical for PtdIns3P
synthesis and PtdIns3P-dependent intracellular functions. Here, we review the current knowledge of the
regulation and function of PtdIns3P and discuss how the view of PtdIns3P changed in the last few years.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Phosphoinositides possess unique properties among signalling
molecules. Differential phosphorylation at the 3, 4 and 5 positions on
the inositol ring allows the generation of seven distinct phosphoinosi-
tides. All seven are naturally occurring in the cell membranes of all
higher eukaryotes. Phosphoinositide kinases and phosphatases can
rapidly convert one speciﬁc phosphoinositide into another. Different
signalling molecules can be produced from phosphoinositides such as
inositol trisphosphate, diacylglycerol and phosphatidic acid. The lipid
tail renders the phosphoinositides obligatory membrane bound,
making themwell suited tomark particularmembrane compartments
or subdomains within a membrane. In this respect, particular
attention has been drawn by 3-phosphorylated phosphoinositides
products of the phosphoinositide 3-kinases (PI3Ks) [1]. Phosphatidy-
linositol 3-phosphate (PtdIns3P) is the most abundant of the 3-
phosphorylated phosphoinositides in resting mammalian cells and
represent 0.1–0.5% of all phosphoinositides [2]. PtdIns3P differs from
the other PI3Ks products mainly because a pool of PtdIns3P is
detectable in normal, unstimulated cells whereas phosphatidylinosi-
tol 3,4-bisphosphate [PtdIns(3,4)P2] and phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3] are normally barely detectable and
their levels increase upon cellular stimulation. Nevertheless, PtdIns3P
levels can also increase upon stimulation due to the de novo synthesis
of a stimulated pool, as discussed below.+44 20 7882 2186.
ll rights reserved.PI3Ks, the family of enzymes responsible for phosphorylation of
position 3 within speciﬁc phosphoinositides, are crucial components
of many signalling pathways playing a pivotal role in many different
physiological events [1]. Mammalian PI3Ks are divided in three
different classes. Class I PI3Ks seem to use phosphatidylinositol 4,5-
bisphosphate [PtdIns(4,5)P2] as preferential substrate in vivo and
therefore their main product is PtdIns(3,4,5)P3. Their activity is
acutely regulated by agonist activation through tyrosine kinase
receptors or G-protein-coupled receptors. We have recently demon-
strated that the class II isoforms PI3K-C2α and PI3K-C2β speciﬁcally
generate PtdIns3P in vivo [3,4]. Although our data suggest that class II
PI3Ks are also activated upon stimulation of tyrosine kinase receptors
and G-protein-coupled receptors, the mechanisms of activation of
class I and class II PI3Ks are likely to be different. For instance, class II
PI3Ks are monomeric and lack a regulatory subunit which can
mediate their activation, as for class I isoforms. Finally, the only
mammalian class III PI3K, hVps34, is also involved in PtdIns3P
synthesis in vivo: whether this occurs only constitutively or the
enzyme can also be activated upon cellular stimulation is still not
completely clear [5]. It is very likely that the three classes of PI3K are
not redundant either because they generate distinct lipid products
which in turn would be able to activate different proteins (as in the
case of class I PI3Ks compared to class II and class III PI3Ks) or
because they are activated in distinct intracellular compartments and
therefore their lipid product likely interacts with distinct proteins (as
in the case of the endosomal hVps34-dependent pool of PtdIns3P
compared to the class II PI3Ks-dependent pool which is generated at
the plasma membrane [3,4]). While for several years attention has
been exclusively focused on class I PI3Ks, there is currently an
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accumulating evidence suggesting their potential involvement in cell
signalling and disease [5,6].
The myotubularin family of phosphatases is another key player in
PtdIns3P metabolism. Myotubularins (MTMs) are members of the
protein tyrosine phosphatase superfamily that remove the 3-
phosphate from PtdIns3P [7]. It has been established that PtdIns3P
and PtdIns(3,5)P2 are the main substrates of MTMs in vivo. In humans,
this family comprises 14 different members. Interestingly, six of these
are catalytically inactive. MTMs seem to localize in different
intracellular compartments and membranes including the plasma
membrane, early and late endosomes, the Golgi apparatus and the
endoplasmic reticulum. This diverse localization of the main PtdIns3P
switch off mechanism may suggest a multiple role for this lipid in
different cellular compartments.
PtdIns3P has a well-established role in trafﬁcking and endocytosis
and readers are referred to excellent reviews on this topic [8–10]
whereas this review will focus on novel aspect of PtdIns3P signalling.
Speciﬁcally, since we have proposed PtdIns3P as a novel dynamic
second messenger and described PtdIns3P binding domains and
potential downstream targets in a recent review [2], here we will
describe how the view of PtdIns3P changed in the last few years and
make personal assessment and interpretation of the data, suggesting
potential future developments.
2. In vivo regulation of PtdIns3P
The intracellular levels of PtdIns3P are regulated by a coordinated
action of kinases (which directly synthesize PtdIns3P from the
precursor PtdIns), phosphatases (which dephosphorylate PtdIns3P
to PtdIns) and kinases/phosphatases which can convert it into other
phosphoinositides (Fig. 1). Intracellular localization of these enzymes
within the cell and/or their relocation upon cellular stimulation is
critical for localized modulation of PtdIns3P levels and they ultimately
determine the speciﬁc intracellular functions of this phosphoinositide
(Table 1). Indeed it has become increasingly evident that different
pools of PtdIns3P exist within a cell, a “constitutive” pool, already
detectable in resting cells, and regulated pools, generated upon
cellular stimulation [2]. Vps34 is thought to be the major player in the
production of constitutive PtdIns3P although the paradigm that this is
the only enzyme responsible for this pool of PtdIns3P in mammalian
cells has been challenged by several observations. First, siRNA of
hVps34 does affect late endosomal structure but not early endosome
morphology and trafﬁcking pathways [11]. This suggests that other
kinases sensitive to the generic PI3K inhibitor wortmannin or
polyphosphoinositide phosphatases are involved in PtdIns3P produc-
tion in early endocytic pathway. Furthermore, localization of EEA1 in
early endosomes, thought to be mediated by its interaction with
PtdIns3P, is more resistant to treatment with wortmannin [11], an
exclusive feature of the class II PI3K isoform PI3K-C2α, which
therefore could be involved in the production of PtdIns3P in early
endosomes. Consistent with this, wortmannin, which completely
blocks the activity of Vps34, does not inhibit entirely intracellular
PtdIns3P levels [2]. The “non-exclusivity” of Vps34 in regulating the
endosomal PtdIns3P is further supported by data suggesting that
PtdIns3P can be generated in early endosomes through an enzymatic
cascade involving class I PI3K and the sequential action of PI 5- and PI
4-phosphatases [12]. Additionally, it has been reported that Type 1a
polyphosphate 4-phosphatase can also produce PtdIns3P through
dephosphorylation of PtdIns(3,4)P2 on endosomes and plasma
membrane [13]. Our recent work demonstrated that the regulated
pools of PtdIns3P are generated through class II PI3Ks activation in
different cellular contexts [2–4]. Indeed our work identiﬁed PtdIns3P
as the main in vivo product of class II PI3Ks. In particular, we reported
that PtdIns3P is generated in insulin responsive cells upon insulin
stimulation [14] through activation of PI3K-C2α [4]. In addition, wedemonstrated that lysophosphatidic acid (LPA) generates PtdIns3P in
different cell lines [3,15] through activation of PI3K-C2β [3]. One of
the major differences between the regulated pools and the constitu-
tive one is the distinct intracellular compartments in which they are
generated. The stimulated PtdIns3P pools are generated at the plasma
membrane after stimulus-induced translocation of the class II PI3Ks to
such compartment [3,4]. It is very likely that PtdIns3P is not
constitutively present at the plasma membrane suggesting that this
lipid may be speciﬁcally generated there by acute stimulation of class
II PI3Ks and therefore it may play a similar role as PtdIns(3,4,5)P3,
recruiting molecules upon cellular stimulation [2]. Whether class II
PI3Ks can only regulate a plasma membrane-associated pool of
PtdIns3P remains to be addressed. In this respect, it is worth
mentioning that PI3K-C2α has been detected in the nucleus [4], in
particular in intranuclear structures known as nuclear speckles [16],
and that we have demonstrated that a GFP-tagged insulin receptor
substrate 3 localizes to the same nuclear structures, in a mechanism
involving binding of its pleckstrin homology (PH) domain to PtdIns3P
[17]. A nuclear accumulation of PtdIns3P was further conﬁrmed by a
study using the PtdIns3P-binding PH domain from CKIP-1 [18].
Moreover, a role for a class II-dependent nuclear pool of PtdIns3P is
supported by data demonstrating accumulation of PI3K-C2β in the
nucleus [19]. Similarly, PI3K-C2α has been detected in trans-Golgi
network [20] and both DFCP1 [21] and its splice variant TAFF-1 [22],
which possess two FYVE domains able to bind PtdIns3P, localized to
the Golgi compartment. Although data seem to suggest that binding to
PtdIns3P is not critical for DFCP1 localization to the Golgi, the
intriguing possibility that PI3K-C2α can regulate a pool of PtdIns3P in
this compartment is worth being further investigated. Furthermore,
whether these pools of PtdIns3P are regulated by cellular stimulation
remains to be addressed. Further evidence of the involvement of class
II PI3Ks in production of PtdIns3P in vivo has been provided in Cae-
norhabditis elegans where inhibition of PtdIns3P degradation (by
downregulation of the phosphatases MTMs) is able to rescue the
phenotype of a Vps34 null mutant [23]. This means that additional
sources of PtdIns3P must exist in C. elegans which are highlighted by
removal of MTMs. Indeed, siRNA knockdown of the C. elegans class II
PI3K reduces the rescue induced by MTMs knockdown indicating that
a class II PI3K-dependent PtdIns3P pool is normally present in C.
elegans and is regulated by MTMs [23]. Finally, are class I PI3Ks able to
produce PtdIns3P? There is no evidence so far indicating that class I
PI3K can directly produce PtdIns3P in vivo. Nevertheless, over-
expression of a constitutively active form of the class I catalytic
subunit p110β leads to accumulation of PtdIns(3,4,5)P3, PtdIns(3,4)P2
and PtdIns3P [24]. Even though this is not a physiological condition, it
suggests that class I PI3Ks may produce PtdIns3P in certain conditions
and in speciﬁc intracellular locations. It must be noted that a Rab5-
dependent p110β activation followed by the action of 4- and 5-
phosphatases has been described, revealing a route for de novo
synthesis of PtdIns3P by dephosphorylation of PtdIns(3,4,5)P3 [12].
While PI3Ks regulate PtdIns3P synthesis, PtdIns3P levels are also
modulated by the action of phosphatases, including MTMs which
convert it back to the precursor PtdIns (Fig. 1). The diverse
intracellular localization of these enzymes suggests that accumulation
of PtdIns3P is tightly regulated in different intracellular compart-
ments. In particular, it has been shown that MTM1, which localizes to
Rab5-positive early endosomes [25], is critical for regulation of early
endosomal PtdIns3P levels [26] whereas MTMR2, which speciﬁcally
localizes to Rab7-positive late endosomes [25], regulates late
endosomal PtdIns3P levels [26]. Finally, PtdIns3P levels are regulated
by kinases/phosphatases that can convert it into other phosphoinosi-
tides, such as the 5-kinase PIKfyve which converts PtdIns3P into
PtdIns(3,5)P2 [27]. Although the amount of PtdIns3P generated
through this route is not elevated, the functional signiﬁcance of
such a regulation has been highlighted by recent data demonstrating
that chemical inhibition of PIKfyve can enhance PtdIns3P-dependent
Fig. 1. Enzymes involved in PtdIns3P turnover.
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ylation of PtdIns(3,5)P2 by the 5-phosphatase FIG4/Sac3 can lead back
to PtdIns3P [8]. Finally, although phosphorylation of PtdIns3P to
generate PtdIns(3,4)P2 has only been detected in vitro (dotted arrow
in Fig. 1), conversion of PtdIns(3,4)P2 to PtdIns(3,4,5)P3 in cells has
been reported [29], as discussed below. What are the roles of the
distinct pools of PtdIns3P inside the cells? It is widely accepted that
the endosomal pool of PtdIns3P regulates intracellular trafﬁcking [9]
whereas our data demonstrated that the class II PI3Ks-dependent,
stimulated pools of PtdIns3P control speciﬁc intracellular functions
such as glucose transport in muscle cells and adipocytes [4,14], cell
migration [3], neurosecretory granules release [28] and activation of
the Ca2+-activated K+ channel KCa3.1 [30]. However, emerging data
indicate that the endosomal pool of PtdIns3P can also contribute to
growth factor signalling by critically regulating maturation of an early
endocytic intermediate, known as APPL endosomes [31]. These data
support the concept that PtdIns3P is a key regulator of intracellular
signalling and they further suggest that this role is not just limited to
the stimulated, plasma membrane-associated pool but that the
endosomal pool can also be involved in regulation of signalling. In
addition, as described above, data indicate that PtdIns3P may play a
major role as a secondmessenger not only via recruitment of proteins
containing different PtdIns3P-interacting domains (such as FYVE, PH
and PX domains [2]) but also as a precursors of other potential second
messengers [32,33].Table 1
Localization of PtdIns3P-regulating enzymes in different intracellular compartments and co
Intracellular compartment PtdIns3P-regulating enzymes
Plasma membrane Class II PI3Ks/MTMs
Early endosomes hVps34? PI3K-C2α? p110β/PI4-/
PI5-phosphatases/MTM1
APPL endosomes ?
Late endosomes hVps34/MTMR2
Trans-Golgi network/clathrin-coated vesicles PI3K-C2α
Nucleus PI3K-C2β
Nuclear speckles PI3K-C2α
Autophagosomes hVps34/Jumpy3. Evolution of 3-phosphorylated phosphoinositides signalling
A recent comparative genomic approach of proteins involved in
phosphoinositides metabolism has identiﬁed four groups of proteins
sharing a similar phylogenetic proﬁle [33]. Interestingly, two of these
groups regulate PtdIns3P turnover, the ﬁrst encompassing class III
PI3K, its regulator p150 (PIK3R4) and active MTM, the second
encompassing PIKfyve, FIG4 and their regulator vacuole morphology
and inheritance mutant 14 (VAC14). The observation that proteins in
each groups co-evolved suggest that PtdIns3P levels [derived from
either PtdIns or PtdIns(3,5)P2] must be tightly coordinated by speciﬁc
kinases and phosphatases. Class III PI3K, Vps34, is the most ancient
forms of PI3Ks and the only one conserved from lower eukaryotes to
plants and mammals [34]. Vps34 seems to be the prototype for other
PI3K in higher eukaryotes. This enzyme is nearly ubiquitous in
eukaryotes, and the role of its main product PtdIns3P in the regulation
of vesicular trafﬁcking in the endosomal/lysosomal system is
maintained in almost all eukaryotes. Budding and ﬁssion yeasts
possess only Vps34 therefore PtdIns3P is the main 3-phosphorylated
phosphoinositide in yeasts [34]. Interestingly, Schizosaccharomyces
pombe, which also possesses Vps34 as its only PI3K, has been shown to
accumulate PtdIns(3,4)P2 and PtdIns(3,4,5)P3 upon deletion of ptn1,
homologue of phosphatase and tensin homolog deleted on chromo-
some ten (PTEN) that speciﬁcally dephosphorylates PtdIns(3,4,5)P3 in
position 3 [35]. Therefore, it has been speculated that PtdIns(3,4,5)P3rresponding PtdIns3P-mediated intracellular functions.
Intracellular functions References
Glucose transport, cell migration,
neurosecretory granules release, KCa3.1 activation
[3,4,14,30,82,83]
Trafﬁcking [11,12,26]
Growth factor receptor trafﬁcking, signalling [31]
Trafﬁcking [26]
Clathrin-mediated trafﬁcking [20]
Cell cycle progression? [19]
? [16,17]
Autophagy [69,72]
Table 2
Number of isoforms of the indicated enzymes present in the listed organisms.
Class I PI3K Class II PI3K Class III PI3K Active myotubularins Dead myotubularins PIKfyve(FAB1)/VAC14/FIG4
Mammals, birds, ﬁsh 4 3 1 8a 6 yes
Drosophila melanogaster 1 1 1 3 3 yes
Caenorhabditis elegans 1 1 1 3 3 yes
Yeasts 0 0 1 1 0 yes
a 7 in Mus musculus and Rattus norvegicus.
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pathway initiated by phosphorylation of PtdIns3P through the action
of speciﬁc 4- and 5-kinases [35,36]. In this respect, PtdIns3P would
represent a key molecule towards generation of the second
messenger PtdIns(3,4,5)P3. Data suggest that this alternative route
of PtdIns(3,4,5)P3 synthesis is conserved in mammalian cells since
conversion of PtdIns(3,4)P2 to PtdIns(3,4,5)P3 by the action of a PIP5K
has been shown to occur upon oxidative stress [29]. In Dictyostelium
discoideum, there are three class I catalytic subunits but no regulatory
subunit as well as class II PI3K. In C. elegans and Drosophila
melanogaster, there are three different PI3Ks, one for each class
(Table 2). In mammalian cells, there are eight PI3K isoforms and
speciﬁcally four members within the class I (catalytic subunits:
p110α, β, δ, γ), three members within the class II (α, β, γ) and one
member within the class III (hVps34) (Table 2). Vps34 is the ancestral
form of PI3K and therefore it could be speculated that its product
PtdIns3P is an ancestral form of 3-phosphoinositides that initially
mediated only primordial functions and eventually evolved to parallel
the increasing complexity of organism and cell functions. In this way,
PtdIns3P evolved into a more sophisticated and efﬁcient system to
recruit molecules to different cellular compartments. Both in vitro and
in vivo data show that class II PI3Ks are also able to produce PtdIns3P,
and therefore they might have emerged as an alternative way to
generate PtdIns3P in different cellular compartments and for different
functions. Consistent with the idea that evolution required an
increasing complexity and speciﬁcity for PtdIns3P-mediated signal-
ling, there is an increasing number of PtdIns3P “regulators” (MTMs)
from lower to higher organisms (Table 2).
4. Rab5: a signalling hub for PtdIns3P production
Rab5 is a small GTPase localized to early endosomes which
controls endocytosis and early endosome dynamics. It regulates the
fusion between endocytic vesicles and early endosomes as well as the
homotypic fusion between early endosomes [37]. The GTP-bound
form of Rab5 is the active form in membrane fusion, and the
expression of a GTPase-deﬁcient mutant induces giant endosomes
in cells [38]. The GTP-bound Rab5 recruits several effector proteins
such as Rabaptin-5 [39] and EEA1 [40].
Among the cytosolic proteins that interact with the active form of
Rab5, hVps34 and p110β have been identiﬁed as Rab5 effectors [41].
Data indicate that Rab5 directly binds p110β and interacts with
hVps34 through binding to the hVps34-interacting protein p150 [41].
Of the two PI3Ks, only hVps34 appears to be required for the early
endosomes fusion activity whereas it has been hypothesized that
p110β may contribute to formation of clathrin-coated vesicles at the
plasma membrane [41]. It has been proposed that the GTPase plays a
role in the localization of hVps34 to the appropriate site in endosome
membranes and therefore regulating PtdIns3P synthesis within such
intracellular compartment. Furthermore it has been reported that a
Rab5-mediated localization of hVps34 is critical during phagocytosis
[42]. It must be noted that interconversions of phosphoinositides play
a pivotal role during phagocytosis and at the subsequent stages of
phagosomal maturation into the phagolysosome [43]. Speciﬁcally
there is a strict requirement for 3-phosphoinositides and acquisition
of EEA1 as essential molecular events necessary for phagosomalmaturation. On the other hand, hVps34 and PtdIns3P are critical for
the default pathway of phagosomal maturation into phagolysosomes.
Another example of a Rab5-dependent activation of hVps34 comes
from Salmonella colonization of host cells during infection and the
maturation of the Salmonella-containing vacuole (SCV). This process
involves the formation of PtdIns3P on its outer leaﬂet. SopB, a
bacterial virulence factor with phosphoinositide phosphatase activity,
was initially proposed to generate PtdIns3P by dephosphorylating
PtdIns(3,4)P2, PtdIns(3,5)P2 and PtdIns(3,4,5)P3 [44]. More recently it
has been shown that SopB does not dephosphorylate PtdIns(3,4)P2/
PtdIns(3,4,5)P3 to produce PtdIns3P [45]. Instead, the phosphatase
activity of SopB is required for Rab5 recruitment to the SCV, where
activated Rab5 associates with Vps34 which is ultimately responsible
for PtdIns3P formation on SCVs. Therefore, SopB mediates PtdIns3P
production on the SCV indirectly through recruitment of Rab5 and its
effector Vps34.
Rab5 appears also to be involved in regulation of the synthesis of
the stimulated pools of PtdIns3P, in particular in the insulin cascade.
Rab5 activation occurs at the plasma membrane and downstream of
the small GTP binding protein TC10 [46]. Speciﬁcally TC10 stimulates
Rab5 activity by recruiting GAPEX-5, a VPS9 domain-containing
guanyl nucleotide exchange factor that forms a complex with TC10.
Overexpression of plasma membrane-localized GAPEX-5 or constitu-
tively active Rab5 promotes PtdIns3P formation and knockdown of
GAPEX-5 or overexpression of a dominant negative Rab5 mutant
blocks the synthesis of PtdIns3P induced by insulin or TC10.
Concomitant with its effect on PtdIns3P levels, knockdown of
GAPEX-5 blocks insulin-stimulated GLUT4 translocation and glucose
uptake which is in part regulated by PtdIns3P [14]. These studies
suggest that the TC10/GAPEX-5/Rab5 axis mediates insulin-stimu-
lated production of PtdIns3P, which regulates trafﬁcking of GLUT4
vesicles. Based on our data indicating that the insulin-dependent pool
of PtdIns3P is speciﬁcally generated through activation of PI3K-C2α
[4], it would be interesting to investigate whether Rab5 can regulate
the activity of this enzyme, maybe by modulating its intracellular
localization, although it must be noticed that no direct binding of
PI3K-C2α with active Rab5 was detected [41].
As described above, there is also evidence indicating that Rab5 can
regulate PtdIns3P generation through an alternative mechanism
involving activation of the class I PI3K p110β, PtdIns(3,4,5)P3
generation and subsequent activation of PI 5- and PI 4-phosphatases
[12]. Indeed PI 5- and PI 4-phosphatase activities were detected in the
eluate from Rab5 GTPγS afﬁnity columns [12]. Rab5 directly interacts
with these phosphatases and stimulates their activity in vitro. The
authors show that extraction of Rab5 from the membrane, inhibited
PtdIns3P production by about 60% whereas increasing the fraction of
Rab5 on the membrane stimulated PtdIns3P more than 2.5-fold [12].
The observation that anti-hVps34 and anti-p110β function blocking
antibodies reduced PtdIns3P production in endosomal fraction by
70% and 30%, respectively, supported the hypothesis that Rab5
modulates PtdIns3P production both by regulation of its direct
synthesis through hVps34 and by p110β-dependent PtdIns(3,4,5)P3
production and subsequent dephosphorylation. Consistent with this
hypothesis, anti-PI 4-phosphatase antibodies induced a comparable
degree of inhibition of PtdIns3P production than p110β [12]. A clear
evidence for the existence of this alternative pathway of PtdIns3P
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carrying a loss of function mutation in the gene encoding the PI 4-
phosphatase. Indeed, together with a twofold increase in PtdIns(3,4)
P2 levels, a decrease in PtdIns3P levels was also detected both in
resting and in stimulated conditions in cells from mutant mice
compared to wild-type animals [12]. The functional signiﬁcance of
this alternative pathway of PtdIns3P synthesis is demonstrated by
the inhibition of transferrin uptake upon downregulation of PI 4- and
PI 5-phosphatase which indicates that both enzymes are involved in
Rab5-dependent endocytosis [12]. Taken together, these data raise
the intriguing possibility that Rab5 may mediate assembly of a
complex containing one PI3K and regulatory phosphatases which can
provide an alternative and possibly tightly regulated source of
localized PtdIns3P.
All these results suggest us that PtdIns3P production through
different routes and in different compartments can occur downstream
of Rab5. Therefore, we hypothesized that Rab5 may act as a signalling
hub for PtdIns3P production. This is an intriguing hypothesis that
requires further studies to be fully validated.
5. PtdIns3P and mTOR signalling
Mammalian target of rapamycin (mTOR) is emerging as a key
regulator of several intracellular processes including autophagy,
mRNA transcription, ribosome biogenesis, angiogenesis, hypoxia/
stress-induced responses andmetabolism [47,48]. mTOR exists in two
complexes [47,49]: mTORC1 controls the anabolic and catabolic
processes described above [47,50–52] whereas mTORC2 regulates
actin cytoskeleton, phosphorylation of the protein kinase PKB/Akt and
of serum- and glucocorticoid-induced protein kinase 1 [47,53–56]. The
list of stimuli able to activate mTORC1 includes growth factors,
hormones (such as insulin), nutrients (including amino acids), cellular
energy and hypoxia. A complex network of intracellular signals and a
ﬁnely regulated cross-talk between them is ultimately responsible for
mTOR activation. Whereas it is well established that class I PI3K
isoforms and PtdIns(3,4,5)P3 are key regulators of mTOR activation,
novel evidence suggests that PtdIns3P is also involved in mTOR
activation.
A ﬁrst indication of a role for PtdIns3P in mTOR regulation came
from one study reporting that hVps34 regulates activation of the
mTOR downstream effector S6K1 [57]. In this study, the authors
showed that overexpression of hVps34 or its regulatory subunit
hVps15 per se in HEK293 and GRC+LR-73 cells was able to increase
the activity of overexpressed HA-tagged S6K1, measured in anti-HA
immunoprecipitates, or the mTOR-dependent S6K1 phosphorylation,
respectively. These data suggested that hVps34 regulates S6K1
activity. Downregulation of hVps34 using siRNA in HeLa cells blocked
the insulin-dependent S6K1 and 4EBP1 phosphorylation. Similarly,
microinjection of inhibitory anti-hVps34 antibodies in GRC+LR-73
blocked the insulin-dependent S6K1 activation measured by a
quantitative analysis of ﬂuorescence of cells incubated with anti-
phospho-Ser235/236 S6. Amino acids or glucose starvation decreased
the activity of endogenous hVps34, suggesting that the basal hVps34
activity is regulated by the presence of nutrients. In parallel, amino
acids starvation reduced exogenous HA-S6K1 activity measured in
anti-HA immunoprecipitates. Whether modulation of hVps34 in these
experiments actually resulted in modulation of the levels of PtdIns3P
was not demonstrated. An indirect demonstration of the role of
PtdIns3P in S6K1 activation came from their observation that
overexpression of the PtdIns3P-binding protein domain GFP-2XFYVE
was able to block the insulin-induced activation of overexpressed
S6K1 in GRC+LR-73 cells and HepG2 cells measured in anti-HA
immunoprecipitates. However, whether the GFP-2XFYVE was only
inhibiting the hVps34-dependent pool or it was also affecting the
insulin-induced pool of PtdIns3P in these particular contexts was not
addressed.In a study published almost simultaneously [58], it was also
reported that overexpression of hVps34 was able to increase the
mTOR-dependent phosphorylation of exogenous S6K1 in HEK293
cells in the presence of amino acids. Consistent with this, siRNAs
against hVps34 or hVps15 decreases the amino acid-induced S6K1
phosphorylation in HeLa cells whereas siRNAs against the class I
PI3K p110α had no effect. Although GFP-2XFYVE overexpression in
HEK293 reduced the amino acids-induced S6K1 phosphorylation, it
must be noted that demonstration of an amino acids-dependent
production of PtdIns3P in vivo was performed using an anti-PtdIns3P
antibody and indirect analysis of ﬂuorescence rather than a direct
analysis of the levels of the phosphoinositide. A more recent study
conﬁrmed that amino acid starvation reduces hVps34 activity in
HEK293 cells whereas re-addition of amino acids restores the
activity to the basal levels of both hVps34 activation and S6K
phosphorylation. This study showed that blockade of intracellular
Ca2+ inhibits the effect of amino acids re-addition [59]. Intracellular
Ca2+ appears to trigger association of Ca2+/calmodulin to hVps34
which in turn regulate hVps34 kinase activity and mTOR activation.
Whether this is due to an increase in PtdIns3P levels induced by
amino acids treatment again relied on the use of anti-PtdIns3P
antibody and ﬂuorescence quantiﬁcation. Despite these data
suggesting that hVps34 is important for mTOR activation especially
in the context of amino acids stimulation, questions still remain
about the role of this PI3K isoform in mTOR activation. For instance,
Vps34 does not appear to be required for TOR activation in D.
melanogaster [60] and RNAi depletion of vps34 and vps15 in C.
elegans does not mimic CeTOR and CeRaptor deﬁciency [61,62].
Furthermore, recent data have questioned the role of Ca2+/
calmodulin in hVps34 activation showing that hVps34 activity is
not affected by treatment of cells with Ca2+ chelants or CaM
inhibitors [63]. Similarly, the authors show that removal of CaM
does not affect hVps34 activity neither Ca2+ chelation blocks
hVps34 activity in vitro [63]. A precise investigation of the direct
role of PtdIns3P and in particular of the contribution of the distinct
intracellular pools of PtdIns3P would greatly improve our under-
standing of the mechanisms of mTOR activation. Due to accumulating
data revealing the critical role of mTOR in several human diseases
including cancer and Type 2 diabetes [64,65], a better understanding
of the role and mechanisms of PtdIns3P-dependent mTOR activation
is urgently needed.
6. PtdIns3P and autophagy
Autophagy is a catabolic process by which cells can degrade
cytosolic components and organelles and recycle macromolecules
when there is a deﬁciency of nutrients. It is involved in a wide array of
cellular events including development, aging, immunity and cell
death [66] and it is evolutionarily conserved and ubiquitous among
eukaryotic cells. In higher eukaryotes, autophagic dysfunction has
been associated with cancer, muscular diseases and neurodegenera-
tion [66]. Autophagic pathways differ in the way cytosolic compo-
nents and organelles are delivered to the lysosome or vacuole. In
recent years, morphological, genetic, biochemical and cell biological
approaches have begun to provide insight into the molecular
mechanisms underlying autophagy.
Autophagy presents a topological challenge for the cell because it
requires delivery of cytosolic material to the lumen of a membrane-
bound compartment, the lysosome. This is solved in an ingenious way
by the formation of a double-membrane vesicle, the autophagosome,
which captures cytosolic proteins and organelles during its transfor-
mation from a planar membrane disk into a sphere. In this way,
cytosolic material ﬁrst becomes luminal and is then delivered for
degradation to the lysosome.
A link between autophagy and PI3Ks was found by the observation
that rapamycin, an inhibitor of TOR, a downstream effector the class I
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reported that wortmannin, a PI3K inhibitor, inhibited autophagy [68].
The apparent discrepancy between these two inhibitors was clariﬁed
when it was demonstrated that two different PI3K products are
involved in autophagy. Indeed, it has been shown that the class I PI3K
product PtdIns(3,4,5)P3 is inhibitory for autophagy [69] whereas
PtdIns3P generated by Vps34 is essential for autophagy. Consistent
with this, blockade of the PtdIns(3,4,5)P3-dependent TOR activation
by rapamycin results in enhanced autophagy, while the overexpres-
sion of PTEN, which reduces the level of PtdIns(3,4,5)P3, stimulates
autophagy [70]. On the other hand, the inhibitory effect of the process
in the presence of wortmannin is explained by the fact that it blocks
Vps34 [71].
In mammalian cells, hVps34 forms a multiprotein complex with
the proautophagic tumour suppressors Beclin1/Atg6, Bif-1 and
UVRAG that initiates autophagosome formation [5]. Distinct
hVps34-containing complexes also regulate endocytic processes
that are critical for late-stage autophagosome–lysosome fusion. In
contrast, Vps34 may also transduce activating nutrient signals to
mTOR [57,58], a negative regulator of autophagy. The importance of
a regulated control of PtdIns3P levels for autophagy induction is
further supported by data revealing the negative role of the
myotubularin Jumpy (MTMR14) and, to a lesser extent MTMR6, in
this cellular process [72]. In particular it has been demonstrated
that Jumpy knock down increases both basal and starvation-
induced autophagy and the total numbers of autophagic organelles
[72]. Exactly what is the role of PtdIns3P in autophagy? Major
insights onto the distribution and function of PtdIns3P have been
recently provided by monitoring its distribution during autophagy
using live imaging, biochemistry and electron microscopy [73–78].
It has been found that PtdIns3P, massively delivered into the
vacuole via autophagy, is highly enriched as a membrane com-
ponent of the elongating isolation membranes and autophagosome
membranes rather than as an enclosed cargo, implying direct
involvement of PtdIns3P in autophagosome formation [79]. These
studies have also helped to answer an unsolved set of questions in
autophagy concerning the signals for autophagosome formation and
the origin of its membrane. By following the dynamics of several
PtdIns3P-binding proteins during amino acid starvation (and
autophagy induction), it has been concluded that at least some
autophagosomes are formed in a starvation-induced, PtdIns3P-
enriched membrane compartment dynamically connected to the
endoplasmic reticulum. The membranes of this compartment have
been named omegasomes from their omega-like shape [79].
PtdIns3P is highly enriched on the inner (concave) surfaces of the
isolation membrane and autophagosome compared to the outer
surfaces. In addition this phosphoinositide is also enriched on
unidentiﬁed structures juxtaposed to the elongating tips of isolation
membranes. PtdIns3P seems to be important for providing
localization clues and perhaps for facilitating the fusion step at
the ﬁnal stage of autophagosome formation. A role for PtdIns3P in
the recruitment of WIPI-I (Atg18), a protein involved in autophago-
some formation, to autophagic membranes is suggested by data
indicating that this protein binds PtdIns3P and, to a lesser extent,
PtdIns3,5P2 [80]. A WIPI-I mutant unable to bind PtdIns3P does not
accumulate at autophagosomal structures [80] whereas Jumpy
knockdown increases WIPI-I recruitment to autophagic membranes
[72], supporting the hypothesis that PtdIns3P is necessary to recruit
WIPI-I at the autophagosomal membranes. Such a conclusion is also
supported by data demonstrating that PtdIns3P binding to Atg18 is
essential to full activity in selective and non-selective autophagy
regulating the proper localization of the Atg18/Atg2 complex to
autophagic membranes [78,81]. It has also been suggested that
PtdIns3P can modulate localization of the Atg12/Atg5/Atg16
complex to autophagic membranes which in turn would affect the
site of Atg8-PE formation [78].7. PtdIns3P, exocytosis and GLUT4 translocation
Evidence indicates that PtdIns3P has a role in exocytosis possibly
in different cellular contexts. First it has been recently shown that this
phosphoinositide plays a critical role in exocytosis of neurosecretory
granules [82,83]. Using a selective probe, it has been reported that
stimulation of exocytosis promoted a transient albeit large increase in
PtdIns3P production on secretory vesicles. Inhibition of PtdIns3P
synthesis [83] impairs secretion whereas accumulation of PtdIns3P
through blockade of its conversion into PtdIns(3,5)P2 increases
secretion [28]. Interestingly, this pool of PtdIns3P is sensitive to
PI3K-C2α knockdown and expression of a catalytically inactive form
of PI3K-C2α and is relatively resistant to wortmannin treatment. This
evidence indicates that this pool of PtdIns3P is generated through
activation of PI3K-C2α. Interestingly it has been shown that PI3K-C2α
activation and PtdIns3P production are controlled by Ca2+ [82] and
that both PI3K-C2α and PtdIns3P are involved in the ATP-dependent
priming of the vesicles [83].
A role for PtdIns3P in regulation of the movement of GLUT4
containing vesicles to the plasma membrane (GLUT4 translocation)
has been recently demonstrated. First we reported that exogenous
PtdIns3P was able to induce GLUT4 translocation, suggesting that the
insulin-dependent pool of this phosphoinositide could play a role in
this process [14]. This hypothesis was supported by the observation
that overexpression of MTM impairs insulin-induced GLUT4 translo-
cation [84]. Evidence that a Rab5-dependent PtdIns3P synthesis is
important for GLUT4 translocation has also been provided [46], as
discussed above. It was proposed that PtdIns3P is important for
translocation and possibly unmasking of the C-terminal domain of
GLUT4 but not insertion into the plasma membrane [85] whereas
other evidence suggested that PtdIns3P might be sufﬁcient to induce
both translocation and insertion into the membrane in the absence of
Munc18c [86] or in 3T3-L1 adipocytes overexpressing 72-kDa inositol
polyphosphate 5-phosphatase [87]. The deﬁnitive demonstration that
the endogenous, insulin-dependent PtdIns3P pool is necessary for
GLUT4 translocation came from our work showing that blockade of
PtdIns3P production through downregulation of PI3K-C2α expression
is able to inhibit the process [4]. On the basis of the wortmannin-
insensitivity and on our observation that exogenous PtdIns3P is able
to move GLUT4 to the cell periphery but it is not sufﬁcient to induce
glucose uptake [14], we suggested that PI3K-C2α/PtdIns3P might be
involved in the initial movement of GLUT4 vesicles to the plasma
membrane although we cannot rule out the possibility that they
might also play a role in the docking and fusion of the vesicles,
consistent with the role of PI3K-C2α in priming of neurosecretory
granules exocytosis [82,83]. Whether PtdIns3P itself is involved in this
process or whether the de novo synthesis of this phosphoinositide
through PI3K-C2α activation is required for its further conversion into
PtdIns3,5P2, whose role in GLUT4 translocation has also been reported
[88], is still a matter of investigation.
8. PtdIns3P and human disease
Extensive reviews describing the role of PtdIns3P in endosomal
trafﬁcking and its link to human disease have been recently published
[8,89].
An increasing number of human genetic diseases including
myopathy and neuropathies are associated with mutations in
enzymes regulating the turnover of PtdIns3P. The PtdIns3P and
PtdIns(3,5)P2 3-phosphatase myotubularin gene is mutated in X-
linked centronuclear myopathy, whereas its homologs MTMR2 and
MTMR13 and the PtdIns(3,5)P2 5-phosphatase SAC3/FIG4 are
implicated in Charcot–Marie–Tooth peripheral neuropathies [90,91].
Mutations in the gene encoding the PtdIns3P 5-kinase PIP5K3/PIKfyve
have been found in patients affected with François–Neetens ﬂeck
corneal dystrophy [92]. Splice variants of PIK3C3 gene, encoding
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schizophrenia [93–95] suggesting that alteration of PtdIns3P synthe-
sis is associated with these diseases. These ﬁnding are particularly
interesting as class II and class III PI3Ks are highly enriched in brain.
Moreover, taking into account the potential role of class II PI3Ks in
insulin action and cancer, it may be tempting to speculate that
impaired PtdIns3P regulation may play a role also in diabetes and
cancer. No evidence has been provided so far in diabetic and cancer
patients about somatic mutations or overexpression of the genes
encoding key players in PtdIns3P metabolism, such as MTMs or class
II/III PI3Ks. Nevertheless, gene expression proﬁling has revealed an
increased expression of the class II isoform PI3K-C2β in several
cancers such as acute myeloid leukemia, glioblastoma and acute
lymphocytic leukemia [96–98]. Furthermore, it has been reported that
different SCLC cell lines overexpress distinct subsets of class I(A) and II
PI3Ks, which results in striking differences in the signalling cascades
activated by stem cell factor [99]. Other evidence supporting a role for
class II PI3K in cancer includes our demonstration that the LPA-
dependent activation of PI3K-C2β is necessary for migration of
ovarian and cervical cancer cells [3]. Taken together these data
indicate that PI3K-C2βmay play a role in cancer development. Vps34
may also play a role in cancer for its involvement in autophagy and
mTOR signalling [5]. Finally, it is noteworthy that polymorphism of
the gene coding for the class II isoform PI3K-C2γ has been found
associated with Type 2 diabetes in a Japanese population [100].
Whether this is associated with impaired PtdIns3Pmetabolism needs
to be determined.
9. Perspectives and conclusions
The major aim of this review was to highlight novel aspects of
PtdIns3P biology and others that remain unclear or controversial.
There are still several unanswered questions in PtdIns3P signalling.
Although mutations in numerous PtdIns3P regulators are associated
with human diseases, the cell-developmentalmechanisms involved in
normal PtdIns3P regulation and responses are not well understood.
Similarly, data suggest that PtdIns3P may play a role in cancer even
though the precise mechanism is not known. PtdIns3P does not seem
to activate Akt and therefore it is probably activating a parallel
pathway to the well-established PtdIns(3,4,5)P3/Akt pathway. The
role of class II PI3Ks still remain largely elusive and unclear even
though our recent work disclose a novel interesting scenario for these
enzymes. An interesting possibility is that the two pathways activated
by PtdIns(3,4,5)P3 and by PtdIns3Pmay converge, as we proposed for
GLUT4 translocation.
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